Disrupting global science from Southeast Asia with AI infrastructure and models.

The biotechnology industry was once defined strictly by scale. Solving complex problems like understanding how proteins fold required a massive physical footprint, sprawling campuses, and thousands of researchers.

For startup founders in Southeast Asia, these heavy requirements were often out of reach. We are now witnessing a structural pivot: the competitive edge has moved from the size of a company’s real estate to the sophistication of its AI models and the specialized infrastructure that supports them.

This shift is fueling an economic expansion that has already redefined the broader regional landscape. By the start of 2026, the APAC biotechnology market has evolved into a powerhouse that was valued at US$432.72 billion last year.

Such momentum is projected to carry the industry toward a staggering US$1.6 trillion valuation by 2034. By maintaining a steady annual growth rate of nearly 15% over the next decade, the region is creating a massive opening for lean startups to lead the next wave of medical innovation.

From wet labs to agentic AI discovery partners

Traditional drug discovery was a wet lab game of slow, manual trials and physical experimentation. We’re seeing the most significant breakthroughs happen in the dry lab, where high-performance computers allow startups to simulate millions of molecular interactions virtually before a single vial is ever opened. A transformative trend emerging in this space is agentic AI, autonomous systems that act as digital laboratory partners. After the dry lab work is carried out, traditional wet lab validation is still a necessary step however the number of experiments needed is vastly reduced.

A prime example is CRISPR-GPT, an agentic AI co-pilot developed through a collaboration between researchers at Stanford, Princeton, and Google DeepMind. Unlike traditional software, CRISPR-GPT can independently navigate complex experimental designs and data analysis, significantly lowering the barrier to entry for lean teams.

In recent trials, researchers with little previous experience in gene editing achieved an 80% editing efficiency on their first attempt by using the system to design their experiments. Such advancements democratise advanced science, empowering a small startup in Southeast Asia to innovate at a speed once reserved for global leaders by reducing experimental cycles from months to weeks

Genomics and Singapore as a Regional Launchpad

Genomics has moved beyond mapping the human genetic code. Today, we are moving from simply observing how life works to actually programming how it behaves.

This trend is turning biology into information science. The real breakthrough lies in combining generative and agentic AI to simulate and predict DNA behaviour in real-time, making computational power, rather than just data, the key differentiator across diverse populations.

Singapore has capitalised on this shift to become a leading global launchpad, building deep research capabilities in Asian biology. According to 2025 research from L.E.K. Consulting, this environment has catalysed a fourfold increase in locally incorporated biotech companies since 2015, all powered by specialised regional data.

This momentum is anchored by the National Precision Medicine (NPM) initiative. By sequencing the genomes of 100,000 people to create a massive Asian Reference Genome, the NPM provides the high-quality data foundation that startups require. This has now expanded into Phase III (SG500K), aiming to sequence 10% of the local population to drive large-scale clinical implementation.

Instead of spending years and millions collecting data, lean startups can now partner with national platforms like PRECISE. These systems provide secure access to anonymised genomic data and electronic health records, allowing small teams to develop the kind of precise, gene-based treatments that were once the exclusive domain of global pharmaceutical giants.

Specialised Infrastructure and the Path Forward

While software and genomic platforms make research accessible, specialised hardware remains the ultimate gatekeeper. A common pitfall for emerging startups is assuming general-purpose cloud systems are enough for complex biological reasoning. Simulating the code of life, from genomic sequencing to protein folding, is one of the most demanding tasks performed today, and standard cloud infrastructure often lacks the power required for these large-scale simulations.

To compete globally, startups in Jakarta or Bangkok need access to specialised AI infrastructure clusters tuned for high speed. Securing approval in a hub with world-class regulatory excellence, such as Singapore’s WHO Maturity Level 4 status, serves as a vital stepping stone to global markets.

Modern innovators now realise that digital strategy is now inseparable from scientific strategy. The era of R&D bloat is giving way to a model where compute is the new capital. With initiatives such as Singapore’s Startup Equity program providing over S$1 billion in co-investment capital for deep tech, the barriers between startups and giants are fading.

The question is no longer whether a lean team in a developing market can challenge global leaders; it is which one will do it first.